Profile data is unavailable for this security.
About the company
Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.
- Revenue in USD (TTM)155.90m
- Net income in USD-170.60m
- Incorporated2007
- Employees534.00
- LocationStandard BioTools Inc2 Tower Place, Suite 2000SOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 266-6000
- Fax+1 (302) 655-5049
- Websitehttps://www.standardbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quanterix Corp | 129.33m | -39.71m | 449.80m | 441.00 | -- | 1.34 | -- | 3.48 | -1.04 | -1.04 | 3.40 | 8.77 | 0.3078 | 2.37 | 4.60 | 293,265.30 | -9.45 | -15.96 | -10.30 | -17.66 | 57.42 | 52.79 | -30.71 | -53.79 | 8.99 | -- | 0.00 | -- | 15.96 | 26.60 | 66.56 | -- | 20.07 | -- |
| Pacific Biosciences of California Inc | 173.15m | -394.24m | 482.38m | 796.00 | -- | 1.07 | -- | 2.79 | -1.46 | -1.46 | 0.64 | 1.65 | 0.1034 | 1.97 | 5.78 | 217,521.40 | -23.55 | -16.19 | -25.40 | -17.81 | 23.81 | 37.35 | -227.69 | -136.21 | 8.64 | -21.87 | 0.6634 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Semler Scientific Inc | 58.94m | 15.91m | 482.70m | 92.00 | 32.42 | 5.54 | 29.16 | 8.19 | 2.05 | 2.05 | 7.58 | 11.99 | 0.6868 | 17.20 | 9.33 | 640,619.60 | 18.54 | 38.83 | 20.37 | 44.41 | 88.05 | 90.22 | 27.00 | 32.58 | 3.09 | -- | 0.00 | -- | 20.28 | 25.98 | 43.69 | 32.64 | -0.3821 | -- |
| Treace Medical Concepts Inc | 202.86m | -61.52m | 494.64m | 516.00 | -- | 4.71 | -- | 2.44 | -0.9924 | -0.9924 | 3.27 | 1.68 | 0.8951 | 1.08 | 8.25 | 393,141.50 | -27.15 | -- | -32.22 | -- | 80.61 | -- | -30.33 | -- | 2.98 | -- | 0.3366 | -- | 31.92 | -- | -15.68 | -- | -- | -- |
| SI-Bone Inc | 157.04m | -37.40m | 515.42m | 344.00 | -- | 3.11 | -- | 3.28 | -0.9108 | -0.9108 | 3.82 | 3.95 | 0.6859 | 1.46 | 7.00 | 456,497.10 | -16.34 | -27.88 | -18.08 | -30.94 | 77.70 | 85.03 | -23.82 | -51.09 | 7.22 | -- | 0.1799 | -- | 30.52 | 20.19 | 29.25 | -- | 52.62 | -- |
| Mesa Laboratories Inc | 228.38m | -245.65m | 547.81m | 736.00 | -- | 3.39 | -- | 2.40 | -45.57 | -45.57 | 42.13 | 29.79 | 0.4186 | 2.74 | 5.96 | 310,298.90 | -45.02 | -9.20 | -54.70 | -9.88 | 62.47 | 60.60 | -107.56 | -28.33 | 0.5106 | 1.35 | 0.5594 | -- | -1.32 | 15.95 | -27,438.28 | -- | 15.26 | 0.00 |
| Surmodics Inc | 126.08m | -11.54m | 559.12m | 389.00 | -- | 4.72 | -- | 4.43 | -0.8145 | -0.8145 | 8.90 | 8.30 | 0.6922 | 2.20 | 6.03 | 324,108.00 | -6.34 | -3.99 | -7.22 | -4.66 | 73.81 | 80.25 | -9.15 | -6.26 | 3.22 | -3.03 | 0.1991 | -- | -4.91 | 4.73 | -651.43 | -- | -12.34 | -- |
| AxoGen Inc | 180.86m | -14.31m | 576.51m | 426.00 | -- | 5.80 | -- | 3.19 | -0.3302 | -0.3302 | 4.16 | 2.26 | 0.9356 | 1.65 | 7.55 | 424,544.60 | -7.40 | -13.92 | -8.49 | -15.84 | 76.13 | 79.74 | -7.91 | -20.28 | 2.47 | -1.50 | 0.3224 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Simulations Plus Inc | 70.01m | 9.95m | 602.82m | 243.00 | 61.38 | 3.30 | 38.60 | 8.61 | 0.4894 | 0.4894 | 3.45 | 9.10 | 0.3659 | -- | 5.55 | 288,119.30 | 5.20 | 6.10 | 5.55 | 6.45 | 61.63 | 74.01 | 14.22 | 18.97 | -- | -- | 0.00 | 45.64 | 17.52 | 15.56 | -0.0703 | 3.01 | 17.07 | 0.00 |
| Standard Biotools Inc | 155.90m | -170.60m | 603.06m | 534.00 | -- | 1.23 | -- | 3.87 | -0.7091 | -0.7091 | 0.5579 | 1.31 | 0.3054 | 2.48 | 6.01 | 291,951.30 | -24.41 | -28.17 | -29.37 | -33.60 | 48.57 | 51.58 | -79.91 | -74.85 | 3.41 | -- | 0.1014 | -- | 8.57 | -1.20 | 60.73 | -- | 50.06 | -- |
| Orthopediatrics Corp | 189.67m | -28.44m | 641.00m | 247.00 | -- | 1.73 | -- | 3.38 | -1.24 | -1.24 | 8.26 | 15.32 | 0.4116 | 0.4509 | 4.71 | 767,906.90 | -6.17 | -5.40 | -6.78 | -5.93 | 73.68 | 75.09 | -15.00 | -15.92 | 3.68 | -29.23 | 0.1638 | -- | 21.62 | 20.91 | -1,767.25 | -- | 28.29 | -- |
| Iradimed Corp | 71.31m | 18.63m | 674.61m | 148.00 | 36.46 | 8.08 | 34.68 | 9.46 | 1.46 | 1.46 | 5.59 | 6.59 | 0.7851 | 1.42 | 6.16 | 481,791.50 | 20.51 | 13.16 | 22.48 | 14.58 | 77.14 | 76.55 | 26.12 | 21.46 | 7.82 | 143.27 | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
| Varex Imaging Corp | 811.00m | -47.70m | 675.26m | 2.30k | -- | 1.27 | -- | 0.8326 | -1.16 | -1.16 | 19.77 | 13.02 | 0.6576 | 2.04 | 5.05 | 352,608.70 | -3.83 | -0.1231 | -4.54 | -0.146 | 31.68 | 31.59 | -5.82 | -0.1748 | 1.97 | 1.40 | 0.4502 | -- | -9.22 | 0.767 | -198.96 | -- | 6.32 | -- |
| Butterfly Network Inc | 76.22m | -98.51m | 700.97m | 225.00 | -- | 3.85 | -- | 9.20 | -0.4708 | -0.4708 | 0.3627 | 0.8537 | 0.2543 | 0.6416 | 4.45 | 338,755.60 | -32.87 | -- | -38.53 | -- | 29.60 | -- | -129.25 | -- | 2.95 | -- | 0.00 | -- | -10.21 | -- | 20.76 | -- | -- | -- |
| Orthofix Medical Inc | 784.25m | -119.03m | 713.84m | 1.63k | -- | 1.36 | -- | 0.9102 | -3.14 | -3.14 | 20.72 | 13.76 | 0.8844 | 1.17 | 6.56 | 479,956.60 | -13.42 | -8.88 | -16.31 | -10.96 | 68.05 | 72.37 | -15.18 | -9.28 | 1.11 | -3.12 | 0.2069 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Figs Inc | 548.65m | 10.84m | 798.70m | 354.00 | 79.82 | 1.98 | 48.23 | 1.46 | 0.059 | 0.059 | 3.08 | 2.38 | 1.11 | 1.33 | 65.26 | 1,549,845.00 | 2.20 | -- | 2.64 | -- | 67.67 | -- | 1.97 | -- | 3.28 | -- | 0.00 | -- | 7.87 | -- | 6.85 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Standard BioTools Inc's reporting currency: US Dollar USD
60.01%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Casdin Capital LLCas of 30 Sep 2024 | 71.25m | 19.20% |
| Viking Global Investors LPas of 30 Sep 2024 | 58.65m | 15.80% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 20.28m | 5.47% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 16.79m | 4.52% |
| Morgan Stanley Investment Management, Inc.as of 30 Sep 2024 | 13.73m | 3.70% |
| Nikko Asset Management Co., Ltd.as of 30 Sep 2024 | 9.58m | 2.58% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 9.57m | 2.58% |
| ARK Investment Management LLCas of 30 Sep 2024 | 8.95m | 2.41% |
| Millennium Management LLCas of 30 Sep 2024 | 6.98m | 1.88% |
| Geode Capital Management LLCas of 30 Sep 2024 | 6.95m | 1.87% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
